Bluejay Diagnostics, Inc. Cash Flow Statement
BJDX|2 years of annual SEC 10-K data (FY2022-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$8M
FY2023
Free Cash Flow
-$9M
FY2023
Capital Expenditures
$704,166
Cash used for long-term assets
Dividends Paid
N/A
FY2023
Bluejay Diagnostics, Inc. used $8M in operating cash flow and negative free cash flow of $9M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -10.44 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
- Negative return on equity: -343.8% ROE
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 |
|---|---|---|
| Net Income | -$10.0M | -$9.3M |
| Depreciation & Amortization | - | $156.6K |
| Operating Cash Flow | -$8.3M | -$7.7M |
| Capital Expenditures | $704.2K | $1.2M |
| Free Cash Flow | -$9.0M | -$8.9M |
| FCF Margin | - | -3590.1% |